Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma
A
Anca Prica
(Princess Margaret Cancer Centre, Toronto)
M
Mark Roschewski
(Center for Cancer Research, Bethesda, MD)
P
Peter Beale
(Walter Reed National Military Medical Center, Bethesda, MD)
S
Stefania Pittaluga
J
Jan Delabie
(University Health Network, Toronto)
C
Claudia Ortega
(University Health Network, Toronto)
R
Robert Kridel
(Princess Margaret Cancer Centre, Toronto)
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 392, Issue 17
Published
May 01, 2025
Pages
1760-1762
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (7)
A
Anca Prica
Princess Margaret Cancer Centre, Toronto
M
Mark Roschewski
Center for Cancer Research, Bethesda, MD
P
Peter Beale
Walter Reed National Military Medical Center, Bethesda, MD
S
Stefania Pittaluga
J
Jan Delabie
University Health Network, Toronto
C
Claudia Ortega
University Health Network, Toronto
R
Robert Kridel
Princess Margaret Cancer Centre, Toronto
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582